Table 1 Characteristics of the fourteen studies included in the meta-analysis.
Author Year | Country | Sample size ASD controls | Age Mean ± SD (range) ASD controls | Sex (F/M) ASD controls | Analytical technology | Biomaterial | BDNF Mean ± SD ASD controls | Unit of measure | Adjusted founders |
|---|---|---|---|---|---|---|---|---|---|
Abdallah17 | Denmark | 359 741 | 0 0 | 68/291 146/595 | Luminex | Serum | 6.77 ± 3.46 6.94 ± 3.51 | ng/ml | Age, gender |
Correia14 | Ireland | 146 50 | 7.1 7.5 | nr | ELISA | Plasma | 40.44 ± 13.87 23.26 ± 12.34 | ng/ml | nr |
Croen19 | America | 84 159 | 0 0 | nr | Luminex | Serum | 0.0541 ± 0.040 0.0537 ± 0.048 | ng/ml | Age, gender |
Halepoto25 | Saudi Arabia | 60 25 | 6 ± 1.72 7.04 ± 1.74 | nr | ELISA | Serum | 0.392 ± 0.243 0.290 ± 0.162 | ng/ml | Age, gender |
Hashimoto13 | Japan | 18 18 | 21.2 ± 2.1 22.2 ± 2.2 | 0/18 0/18 | ELISA | Serum | 25.6 ± 2.15 61.6 ± 10.9 | ng/ml | Age |
Kasarpalkar26 | India | 48 29 | 7.4 7.4 | nr | ELISA | Serum | 250.56 ± 92.7 225.16 ± 79.54 | ng/ml | Age |
Katoh-Semba23 | Japan | 56 218 | <60 <60 | nr | ELISA | Serum | 0.359 ± 0.277 0.331 ± 0.187 | ng/ml | Age |
Miyazaki24 | Japan | 18 16 | 7.6 ± 6.1 23.3 ± 0.9 | 1/17 11/5 | ELISA | Serum | 25.22 ± 2.45 17.5 ± 2.00 | ng/ml | nr |
Nelson18 | America | 69 54 | 0 0 | 8/61 27/27 | RIAC | Serum | 0.0374 ± 0.0199 0.0133 ± 0.005 | ng/ml | nr |
Nelson20 | America | 27 20 | 0 0 | nr | Luminex and ELISA | Serum | 3.404 ± 1.131 3.299 ± 0.844 | ng/ml | Mean gestational age, birth weight |
Ricci15 | Italy | 29 29 | 2–21 2–21 | 2/27 2/27 | ELISA | Serum | 0.728 ± 0.455 0.351 ± 0.347 | ng/ml | Age, gender |
Wang16 | China | 75 75 | 4.0 ± 1.25 4.0 ± 1.25 | 13/62 13/62 | ELISA | Serum | 17.59 ± 5.55 11.21 ± 2.79 | ng/ml | Age, gender |
Zhang21 | China | 60 60 | 3.78 ± 1.22 3.78 ± 1.22 | 12/48 12/48 | ELISA | Serum | 17.6 ± 5.7 11.5 ± 3.1 | ng/ml | Age, gender |
Meng22 | China | 82 82 | 4.02 ± 1.27 4.02 ± 1.27 | 17/65 17/65 | ELISA | Serum | 17.75 ± 5.43 11.49 ± 2.85 | ng/ml | Age, gender |
